Undisclosed CTLA4 inhibitor antibody therapeutic
/ Tikcro Technologies, Weizmann Institute of Science
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 04, 2019
Single cell analysis reveals the pivotal role of the innate immune compartment in aCTLA-4 anti-tumor response.
(CRI-CIMT-EATI-AACR 2019)
- "Finally, a vast tissue repair signature was observed in later time points of aCTLA4 mIgG2a treatment, comprised of MRC1+ macrophages, neutrophils, and myeloid-derived suppressor cells (MDSCs), while CD8 T cell abundance declined. In summary, our findings provide an in-depth view of the differences in mechanisms of action between an aCTLA4 blocking mAb, and an optimized blocking-depleting mAb, emphasizing how FcgRs co-engagement leads to enhanced anti-tumor response via the innate immune compartment."
April 05, 2019
A CTLA4 antibody with enhanced properties
(AACR 2019)
- "Background: Immune therapy has been viewed in recent years as a major new path in oncology greatly due to the pioneering success in clinical practice of Yervoy (Ipilimumab), a CTLA-4 monoclonal antibody...Synergetic activation of T-cell activation is observed upon a combined treatment of PBMC cells with TikAb and Nivolumab (a PD-1 monoclonal Ab)... We present TikAb - a new full human CTLA4 antibody with enhanced properties in values determined in-vitro and in-vivo. These observation support further examination of TikAb as a therapeutic candidate to treat cancer which may allow a lower treatment dose with an improved efficacy to peers."
1 to 2
Of
2
Go to page
1